Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE). // The Breast. – URL: https://www.sciencedirect.com/science/article/pii/S0960977626002663?dgcid=rss_sd_all
Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE). The Breast. https://www.sciencedirect.com/science/article/pii/S0960977626002663?dgcid=rss_sd_all
“Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE).” The Breast.
@article{article67547,
title = {Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)},
journal = {The Breast},
url = {https://www.sciencedirect.com/science/article/pii/S0960977626002663?dgcid=rss_sd_all}
}
ABSTRACT Objectives The aim of this study was to determine whether certain cephalometric findings can predict the future need for orthognathic surgery (OS) in cleft lip (CL), cleft palate (CP), unilateral cleft lip and palate (UCLP),...